915407-78-2

Upstream product

• 915407-77-1 C₃₈H₃₈FN₃O₄Si 

Downstream Products

• 915407-79-3 C₃₃H₂₈FN₃O₄S 
• 915409-11-9 C₃₇H₂₉FN₄O₄S 
• 915408-10-5 C₃₇H₃₁FN₄O₄S₂ 
• 915408-07-0 C₃₆H₃₀FN₅O₄S 
• 915409-08-4 C₃₄H₂₇F₄N₃O₄S 
• 915409-30-2 4-nitrophenyl 9-(benzhydryloxy)-7-(4-fluorobenzyl)-7,8-dihydro-8-oxo-6H-pyrrolo[3,4-g]quinolin-5-ylmethylcarbamate 
• 915409-05-1 C₄₄H₃₇FN₄O₄S 
• 915408-13-8 C₃₄H₂₈FN₃O₄S 
• 915408-15-0 C₃₅H₂₈FN₃O₅ 
• 915407-88-4 C₃₄H₃₁FN₄O₄S 
• 915408-18-3 N-(9-(benzyhdryloxy)-7-(4-fluorobenzyl)-8-oxo-7,8-dihydro-6H-pyrrolo[3,4-g]quinolin-5-yl)-N-methylacetamide 
• 915409-31-3 1-(9-(benzhydryloxy)-7-(4-fluorobenzyl)-8-oxo-7,8-dihydro-6H-pyrrolo[3,4-g]quinolin-5-yl)-1,3,3-trimethylurea 
• 915408-82-1 tert-butyl N-(9-(benzhydryloxy)-7-(4-fluorobenzyl)-8-oxo-7,8-dihydro-6H-pyrrolo[3,4-g]quinolin-5-yl)-N-methylsulfamoylcarbamate 
• 959404-74-1 C₃₃H₂₇ClFN₃O₄S 

Relevant academic research and scientific papers

Tricyclic HIV integrase inhibitors: Potent and orally bioavailable C5-aza analogs

A series of C5-aza tricyclic HIV integrase inhibitors was prepared. A highly potent and orally bioavailable compound (compound 9) was identified and selected for development.

Integrase inhibitor compounds

Tricyclic compounds, protected intermediates thereof, and methods for inhibition of HIV-integrase are disclosed.